About Us | Pharma Tech Outlook APAC
Pharma Tech Outlook

About Pharma Tech Outlook APAC

Pharma Tech Outlook APAC (ISSN 2644-2787 | Digital ISSN 2644-2787) is an industry magazine focused on the APAC pharmaceutical and life sciences technology landscape, helping organizations navigate a sector defined by regulatory complexity, scientific advancement, and evolving patient expectations. Founded in 2014, the magazine reaches over 79,000 qualified subscribers across APAC.

At its core, Pharma Tech Outlook APAC operates as a peer-driven platform where industry leaders and decision-makers share real-world insights, challenges, and strategies. The publication emphasizes practical, experience-led perspectives, offering a grounded view of how pharmaceutical organizations are adopting technology to improve development, manufacturing, and compliance outcomes.

 

OUR Mission

Pharma Tech Outlook APAC aims to empower organizations and industry leaders to make informed decisions on the technologies, strategies, and solutions shaping the future of pharmaceutical innovation. As a knowledge-sharing platform, it bridges the gap between pharmaceutical companies, technology providers, and stakeholders working to enhance efficiency, ensure compliance, and improve patient outcomes.

Editorial Focus and Coverage

Pharma Tech Outlook APAC features perspectives from pharmaceutical executives, researchers, and technology leaders on how organizations evaluate, adopt, and scale solutions across the pharma ecosystem. The publication covers key areas such as drug design and development, manufacturing processes, drug delivery systems, regulatory compliance, infrastructure, and emerging pharmaceutical technologies.

Alongside leadership insights, the magazine highlights organizations delivering impactful solutions across pharmaceutical technologies, tools, and services. Companies are identified through a structured methodology, involving nominations from the publication’s subscriber network across APAC, combined with editorial research and insights from an industry advisory panel, ensuring a credible and balanced view of the evolving pharmaceutical landscape.

As the industry adapts to new models of data-driven decision-making, personalized medicine, and regulatory oversight, Pharma Tech Outlook APAC captures how organizations are transforming innovation into scalable and compliant solutions.

With editorial offices in Singapore; Fort Lauderdale, FL; and London, UK, Pharma Tech Outlook APAC brings a global perspective to the developments shaping the pharmaceutical technology ecosystem.

 
Who Contributes to Pharma Tech Outlook APAC
  • 100+ CXOs and senior leaders from public enterprises

  • 600+ CXOs and senior leaders from private companies

  • Industry leaders responsible for research, development, manufacturing, regulatory compliance, and pharmaceutical innovation

These contributors include executives, researchers, and industry specialists who bring firsthand experience and practical insight into the evolving pharmaceutical landscape. Their perspectives reflect individual expertise and are intended to inform broader industry conversations.

 
Editorial Policy and Standards

Pharma Tech Outlook APAC maintains a contributor-driven, insight-focused editorial policy. The publication emphasizes accuracy, clarity, and practical relevance for decision-makers, while presenting a balanced mix of expert commentary and curated industry perspectives. This ensures readers can engage with the content confidently and understand its context within the broader pharmaceutical ecosystem.

 
Select Recognized Company Testimonials

EP-PharmaLine

Azusa Miwa, Business Planning & Promotion Div.

“EP-PharmaLine was thrilled to be featured in Pharma Tech Outlook. We are already seeing an increase in interest and inquiries from potential clients, such as foreign pharmaceutical companies planning to start new businesses in Japan. This has also led to gaining further trust from our existing clients, bringing immense value to our business. We would highly recommend Pharma Tech Outlook to any business looking to gain exposure and establish themselves as a leader in their industry”

Azusa Miwa, Business Planning & Promotion Div.

Akadeum Life Sciences

Ken Gordon, VP, Commercial

“Akadeum Life Sciences was thrilled to be featured in Pharma Tech Outlook, and we’ve been incredibly impressed with the reprints that we’ve received. They’ve been a valuable asset for our sales team, and we’re already seeing an increase in interest from potential clients as a result. We would highly recommend Pharma Tech Outlook to any business looking to gain exposure and establish themselves as a leader in their industry.”

Ken Gordon, VP, Commercial

De Dietrich Process Systems

Jennifer Mayo, Marketing Specialist

“De Dietrich Process Systems was thrilled to be featured in Pharma Tech Outlook, and we’ve been incredibly impressed with the reprints that we’ve received. We would highly recommend Pharma Tech Outlook to any business looking to gain exposure and establish themselves as a leader in their industry”

Jennifer Mayo, Marketing Specialist

Psycheceutical

MICHAEL HLAVSA, Chief Financial Officer

“Recognition by Pharma Tech Outlook is a testament to our company’s dedication to innovating state-of-the-art drug delivery technologies. We are proud to be among Pharma Tech Outlook’s featured companies and recognize the publication for their commitment to showcasing truly next-generation solutions at the forefront of the industry”

MICHAEL HLAVSA, Chief Financial Officer
Insights From Public Company Thought Leaders

CSL [ASX: CSL]

Navigating Global R&D and Pharmacokinetics In Oncology

Rose Fida, Executive Director, Program & Performance Excellence, Global R&D Portfolio & Operations Excellence

Navigating Global R&D and Pharmacokinetics In Oncology